Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Antithrombotic Therapy: An Abbreviated Reference for Clinicians

Antithrombotic Therapy: An Abbreviated Reference for Clinicians Abstract Antithrombotic therapy is a mainstay in the treatment of patients with thromboembolic diseases of the arterial and venous circulatory systems. Continued work and investigation has provided much-needed information directly applicable to meeting high standards of patient care. The American College of Chest Physicians Consensus Conference on Antithrombotic Therapy has been instrumental in developing guidelines. This article is a synopsis of the proposed guidelines, including recent updates and information that will likely influence future receommendations. (Arch Intern Med. 1995;155:149-161) References 1. Dalen JE, Hirsh J, eds. Third ACCP Consensus Conference on Antithrombotic Therapy. Chest . 1992;102:303S-549S.Crossref 2. Raschke RA, Reilly BM, Guidtry JR, Fontanta JR, Srinvivas S. A weight-based heparin dosing nomogram compared with a 'standard care' nomogram. Ann Intern Med . 1993;119:874-881.Crossref 3. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet . 1993; 342:1523-1528.Crossref 4. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med . 1993;329:524-525.Crossref 5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet . 1993;342:1255-1262. 6. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet . 1994; 343:687-691. 7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med . 1993;329:673-682.Crossref 8. O'Connor CM, Meese R, Carney R, et al, from the Duke University Clinical Cardiology Study (DUCCS) 1. A randomized trial of intravenous heparin conjunction with anistreplase (APSAC) in acute myocardial infarction. J Am Coll Cardiol . 1994;23:11-18. 9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ . 1994;308:81-106.Crossref 10. Pantrano C. Aspirin as an antiplatelet drug. N Engl J Med . 1994;330:1287-1294.Crossref 11. Canon CP, McCabe CH, Henry TD, et al, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the TIMI 5 trial. J Am Coll Cardiol . 1994;23:993-1003. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Antithrombotic Therapy: An Abbreviated Reference for Clinicians

Loading next page...
 
/lp/american-medical-association/antithrombotic-therapy-an-abbreviated-reference-for-clinicians-wSFOp0pWwG
Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1995.00430020034005
Publisher site
See Article on Publisher Site

Abstract

Abstract Antithrombotic therapy is a mainstay in the treatment of patients with thromboembolic diseases of the arterial and venous circulatory systems. Continued work and investigation has provided much-needed information directly applicable to meeting high standards of patient care. The American College of Chest Physicians Consensus Conference on Antithrombotic Therapy has been instrumental in developing guidelines. This article is a synopsis of the proposed guidelines, including recent updates and information that will likely influence future receommendations. (Arch Intern Med. 1995;155:149-161) References 1. Dalen JE, Hirsh J, eds. Third ACCP Consensus Conference on Antithrombotic Therapy. Chest . 1992;102:303S-549S.Crossref 2. Raschke RA, Reilly BM, Guidtry JR, Fontanta JR, Srinvivas S. A weight-based heparin dosing nomogram compared with a 'standard care' nomogram. Ann Intern Med . 1993;119:874-881.Crossref 3. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet . 1993; 342:1523-1528.Crossref 4. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med . 1993;329:524-525.Crossref 5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet . 1993;342:1255-1262. 6. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet . 1994; 343:687-691. 7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med . 1993;329:673-682.Crossref 8. O'Connor CM, Meese R, Carney R, et al, from the Duke University Clinical Cardiology Study (DUCCS) 1. A randomized trial of intravenous heparin conjunction with anistreplase (APSAC) in acute myocardial infarction. J Am Coll Cardiol . 1994;23:11-18. 9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ . 1994;308:81-106.Crossref 10. Pantrano C. Aspirin as an antiplatelet drug. N Engl J Med . 1994;330:1287-1294.Crossref 11. Canon CP, McCabe CH, Henry TD, et al, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the TIMI 5 trial. J Am Coll Cardiol . 1994;23:993-1003.

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jan 23, 1995

References